| AJTR Copyright © 2009-present, All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711 |
Am J Transl Res 2013;5(5):470-480
Review Article
The role of IL-27 in the induction of anti-tumor cytotoxic T lymphocyte
response
Zhenzhen Liu, Jianhua Yu, William E Carson III, Xue-Feng Bai
Department of Pathology and Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
Received May 13, 2013; Accepted July 6, 2013; Epub August 15, 2013; Published August 30, 2013
Abstract: Cytotoxic T lymphocyte (CTL) response is a critical component of the immune response to tumors,
therefore optimal induction of CTL responses to tumor antigens is highly desired for developing efficient cancer
immunotherapy. IL-27 is a member of the IL-12 family of cytokines that is comprised of an IL-12 p40-related
protein subunit, EBV-induced gene 3 (EBI3), and a p35-related subunit, p28. IL-27 functions through IL-27R and
has been shown to have potent anti-tumor activity via activation of a variety of immune components, including
anti-tumor CD8+ T cell responses. However, the exact mechanisms of how IL-27 enhances anti-tumor CD8+ T
cell responses are not fully understood. In this paper we mainly discuss the evidences that suggest novel
mechanisms by which IL-27 enhances anti-tumor CTL responses, including IL-27 inhibition of activation-induced
cell death; the phenotypes of IL-27-stimulated CTLs; IL-27-induced CTL IL-10/IL-21 production and
IL-27-mediated suppression of regulatory T cell responses. These evidences suggest that IL-27 may have a
great potential to be utilized in boosting anti-tumor CTL responses in human cancer patients. (AJTR1305009).
Keywords: IL-27, anti-tumor cytotoxic T lymphocyte (CTLs), cancer, p28, p35, p53, IL-21
Address correspondence to: Dr. Xue-Feng Bai, Department of Pathology and Comprehensive Cancer Center,
Ohio State University Wexner Medical Center, 129 Hamilton Hall, 1645 Neil Avenue, Columbus, OH 43210, USA.
Tel: 614-292-8649; Fax: 614-292-7072; E-mail: Xue-Feng.Bai@osumc.edu
Review Article
The role of IL-27 in the induction of anti-tumor cytotoxic T lymphocyte
response
Zhenzhen Liu, Jianhua Yu, William E Carson III, Xue-Feng Bai
Department of Pathology and Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
Received May 13, 2013; Accepted July 6, 2013; Epub August 15, 2013; Published August 30, 2013
Abstract: Cytotoxic T lymphocyte (CTL) response is a critical component of the immune response to tumors,
therefore optimal induction of CTL responses to tumor antigens is highly desired for developing efficient cancer
immunotherapy. IL-27 is a member of the IL-12 family of cytokines that is comprised of an IL-12 p40-related
protein subunit, EBV-induced gene 3 (EBI3), and a p35-related subunit, p28. IL-27 functions through IL-27R and
has been shown to have potent anti-tumor activity via activation of a variety of immune components, including
anti-tumor CD8+ T cell responses. However, the exact mechanisms of how IL-27 enhances anti-tumor CD8+ T
cell responses are not fully understood. In this paper we mainly discuss the evidences that suggest novel
mechanisms by which IL-27 enhances anti-tumor CTL responses, including IL-27 inhibition of activation-induced
cell death; the phenotypes of IL-27-stimulated CTLs; IL-27-induced CTL IL-10/IL-21 production and
IL-27-mediated suppression of regulatory T cell responses. These evidences suggest that IL-27 may have a
great potential to be utilized in boosting anti-tumor CTL responses in human cancer patients. (AJTR1305009).
Keywords: IL-27, anti-tumor cytotoxic T lymphocyte (CTLs), cancer, p28, p35, p53, IL-21
Address correspondence to: Dr. Xue-Feng Bai, Department of Pathology and Comprehensive Cancer Center,
Ohio State University Wexner Medical Center, 129 Hamilton Hall, 1645 Neil Avenue, Columbus, OH 43210, USA.
Tel: 614-292-8649; Fax: 614-292-7072; E-mail: Xue-Feng.Bai@osumc.edu
 | |  | |  | |  | |  | |  | |  |